ARWR

Arrowhead Pharma

• Simply Wall St·2d ago

  Can Arrowhead Pharmaceuticals (ARWR) Turn RNAi Obesity Ambitions Into a Durable Cardiometabolic Moat?

• Simply Wall St·4d ago

  Arrowhead Pharmaceuticals (ARWR) Valuation Check After New Plozasiran And ARO-INHBE Clinical Updates

• TipRanks·6d ago

  Analysts’ Top Healthcare Picks: Arrowhead Pharmaceuticals (ARWR), Veeva Systems (VEEV)

• Seeking Alpha·06/03 01:40

  Madrigal Pharmaceuticals Could Become The Next Vertex

• PUBT·06/02 11:30

  Arrowhead Pharmaceuticals joins Jefferies Global Healthcare Conference fireside chat

• TipRanks·06/01 13:30

  Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)

• Simply Wall St·05/28 20:10

  Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After New Plozasiran And ARO INHBE Clinical Results

• TipRanks·05/28 16:33

  Arrowhead’s Inhaled ARO-RAGE Asthma Trial Enters Active Recruitment, Keeping a Key Pipeline Catalyst in Play

• TipRanks·05/28 14:26

  Arrowhead Pharmaceuticals (ARWR) Gets a Buy from H.C. Wainwright

• TipRanks·05/27 21:15

  Arrowhead Pharmaceuticals: Buy Rating Reaffirmed as ARO-INHBE Data Strengthen Outlook and $100 Price Target Maintained

• TipRanks·05/27 11:20

  Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE

• Benzinga·05/27 11:09

  Arrowhead Presents Interim Results From Phase 1/2a Clinical Trial Of ARO-INHBE, Investigational RNAi Therapeutic Developed As Potential Treatment For Obesity And Metabolic Dysfunction-Associated Steatohepatitis

• PUBT·05/27 11:01

  Arrowhead posts Phase 1/2a data showing ARO-INHBE cuts liver fat 44% in obese adults

• TipRanks·05/26 16:29

  Arrowhead presents clinical cardiometabolic data at EAS Congress

• PUBT·05/26 14:18

  Arrowhead Pharmaceuticals posts plozasiran renal, hepatic impairment study presentation